TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference CallBusiness Wire · 6 days ago
Reviewing Innovative Eyewear (NASDAQ:LUCY) and TriSalus Life Sciences (NASDAQ:TLSI)Defense World · Oct 1, 2026
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key SupportBenzinga · Sep 23, 2026
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On WednesdayBenzinga · Sep 23, 2026
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver EmbolizationBusiness Wire · Sep 22, 2026
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment ConferenceBusiness Wire · Aug 31, 2026TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.16 | -$0.16 | Miss |
| May 12, 2026 | -$0.16 | -$0.33 | Miss |
| Mar 5, 2026 | -$0.13 | -$0.21 | Miss |
| Nov 13, 2025 | -$0.17 | -$0.96 | Miss |
| Aug 12, 2025 | -$0.22 | -$0.27 | Miss |
| May 15, 2025 | -$0.20 | -$0.33 | Miss |